Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Variant||FGFR2 - TACC1|
|Gene Variant Descriptions||FGFR2-TACC1 results from the fusion of FGFR2 and TACC1 (PMID: 30420614). FGFR2-TACC1 has been identified in intrahepatic cholangiocarcinoma (PMID: 30420614), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Feb 2020).|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - TACC1||intrahepatic cholangiocarcinoma||predicted - resistant||Derazantinib||Case Reports/Case Series||Actionable||In a Phase Ib/II trial, a patient with intrahepatic cholangiocarcinoma harboring FGFR2-TACC1 demonstrated progressive disease when treated with Derazantinib (ARQ 087) (PMID: 30420614; NCT01752920).||30420614|
|Molecular Profile||Protein Effect||Treatment Approaches|
|FGFR2 - TACC1||unknown|